Company Overview More
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company’s lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca’s checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
CEO: Cannell, Thomas R.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

Moomoo > Quotes > SESN Sesen Bio > Detailed Quotes

SESN Sesen Bio

1.195+0.045+3.91%
Trading Session 10/28 14:05 ET
High
1.280
Open
1.160
Turnover
19.02M
Low
1.140
Prev.Close
1.150
Volume
15.68M
Market Cap
234.22M
P/E(TTM)
Loss
52Wk High
6.040
Shares
196.00M
P/E
Loss
52Wk Low
0.700
H Mkt Cap
234.17M
Bid-Ask Ratio
57.12%
Historical High
6.040
H Shares
195.96M
Vol. Ratio
0.69
Historical Low
0.370
Dividend TTM
--
Div Yield TTM
--
P/B
4.74
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
8.00%
Amplitude
12.17%
Avg Price
1.213
Min Trading Unit
1
Float Market Cap
234.17M
Bid-Ask Ratio
57.12%
Historical High
6.040
Float
195.96M
Vol. Ratio
0.69
Historical Low
0.370
Dividend TTM
--
P/B
4.74
Dividend LFY
--
Turnover Ratio
8.00%
Amplitude
12.17%
Avg Price
1.213
Min Trading Unit
1
Price Forecast

Loading...

News